Cyclothiazide reverses AMPA receptor antagonism of the 2,3-benzodiazepine, GYKI 53655

Eur J Pharmacol. 1993 Jan 15;244(2):193-4. doi: 10.1016/0922-4106(93)90027-7.

Abstract

On rat cortical slices, cyclothiazide, 1-100 microM, (ED50 = 7.1 +/- 1.1 microM) enhanced the depolarizing action of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionate (AMPA) but not that of N-methyl-D-aspartate (NMDA). Cyclothiazide 10 microM also reversed the action of a 2,3-benzodiazepine, GYKI 53655, which is a non-competitive AMPA receptor antagonist, but not that of the quinoxalinedione, NBQX, which is a competitive AMPA receptor antagonist.

MeSH terms

  • Animals
  • Benzodiazepines / antagonists & inhibitors*
  • Benzodiazepines / pharmacology
  • Benzothiadiazines / pharmacology*
  • Cerebral Cortex / drug effects
  • Cerebral Cortex / metabolism
  • Diuretics
  • Excitatory Amino Acid Antagonists*
  • Ibotenic Acid / analogs & derivatives
  • Ibotenic Acid / pharmacology
  • In Vitro Techniques
  • Kainic Acid / pharmacology
  • N-Methylaspartate / pharmacology
  • Quinoxalines / pharmacology
  • Rats
  • Receptors, AMPA
  • Sodium Chloride Symporter Inhibitors / pharmacology*
  • alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid

Substances

  • Benzothiadiazines
  • Diuretics
  • Excitatory Amino Acid Antagonists
  • Quinoxalines
  • Receptors, AMPA
  • Sodium Chloride Symporter Inhibitors
  • 2,3-dioxo-6-nitro-7-sulfamoylbenzo(f)quinoxaline
  • Benzodiazepines
  • GYKI 53655
  • Ibotenic Acid
  • N-Methylaspartate
  • alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid
  • cyclothiazide
  • Kainic Acid